

Title (en)
MOLECULAR DIAGNOSTIC TEST FOR CANCER

Title (de)
MOLEKULARER DIAGNOSETEST AUF KREBS

Title (fr)
TEST DE DIAGNOSTIC MOLÉCULAIRE POUR LE CANCER

Publication
EP 2975399 B1 20220511 (EN)

Application
EP 15181181 A 20110915

Priority
• US 38320110 P 20100915
• US 201161490039 P 20110525
• EP 11825959 A 20110915
• US 2011051803 W 20110915

Abstract (en)
[origin: WO2012037378A2] Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

IPC 8 full level
A61K 33/243 (2019.01); **C12Q 1/6886** (2018.01); **G16B 25/00** (2019.01); **G16B 25/10** (2019.01); **G16B 25/20** (2019.01); **G16B 40/00** (2019.01); **G16B 40/20** (2019.01)

CPC (source: CN EP KR US)
A61K 33/243 (2018.12 - CN EP US); **C12Q 1/6876** (2013.01 - KR US); **C12Q 1/6886** (2013.01 - CN EP KR US); **G01N 33/48** (2013.01 - KR); **G01N 33/57415** (2013.01 - KR); **G01N 33/57449** (2013.01 - KR); **G01N 33/582** (2013.01 - KR); **G16B 25/00** (2019.01 - CN EP US); **G16B 25/10** (2019.01 - CN EP US); **G16B 40/00** (2019.01 - CN EP US); **G16B 40/20** (2019.01 - CN EP US); **G16H 50/30** (2017.12 - EP US); **C12Q 2600/106** (2013.01 - CN EP KR US); **C12Q 2600/112** (2013.01 - US); **C12Q 2600/158** (2013.01 - CN EP KR US); **C40B 30/04** (2013.01 - US)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2012037378 A2 20120322; WO 2012037378 A3 20120705; AU 2011302004 A1 20130404; AU 2011302004 B2 20151029; AU 2016200494 A1 20160407; AU 2016200494 B2 20171116; BR 112013006207 A2 20171024; CA 2811015 A1 20120322; CN 103299188 A 20130911; CN 103299188 B 20170315; CN 106978480 A 20170725; EA 201390370 A1 20130730; EP 2619574 A2 20130731; EP 2619574 A4 20140312; EP 2619574 B1 20201028; EP 2975399 A1 20160120; EP 2975399 B1 20220511; HK 1216665 A1 20161125; JP 2013537045 A 20130930; JP 2017093440 A 20170601; KR 20130115250 A 20131021; MX 2013002879 A 20130517; MX 344636 B 20170104; MY 166040 A 20180521; NZ 608459 A 20151030; NZ 620799 A 20151030; NZ 712823 A 20170526; SG 10201610027V A 20170127; SG 188397 A1 20130430; US 10214777 B2 20190226; US 10378066 B2 20190813; US 2014031260 A1 20140130; US 2014051591 A1 20140220; US 2016060705 A1 20160303; US 2017198360 A1 20170713; US 9670547 B2 20170606; US 9677140 B2 20170613; ZA 201301567 B 20160428; ZA 201508689 B 20210526

DOCDB simple family (application)
US 2011051803 W 20110915; AU 2011302004 A 20110915; AU 2016200494 A 20160128; BR 112013006207 A 20110915; CA 2811015 A 20110915; CN 201180047116 A 20110915; CN 201710082290 A 20110915; EA 201390370 A 20110915; EP 11825959 A 20110915; EP 15181181 A 20110915; HK 16104700 A 20131223; JP 2013529331 A 20110915; JP 2016238969 A 20161209; KR 20137009145 A 20110915; MX 2013002879 A 20110915; MY PI2013000762 A 20110915; NZ 60845911 A 20110915; NZ 62079911 A 20110915; NZ 71282311 A 20110915; SG 10201610027V A 20110915; SG 2013016175 A 20110915; US 201113821404 A 20110915; US 201314047949 A 20131007; US 201514825480 A 20150813; US 201715426923 A 20170207; ZA 201301567 A 20130228; ZA 201508689 A 20151126